Neurocognitive Impairment | Expert Opinion

web-BRAIN-nar hosts live and on-demand webcasts on neurocognitive disorders related to Alzheimer’s disease and of vascular origin. We aim to serve the needs of the health care professionals specifically in, but not limited to, Asia. We hope web-BRAIN-nar can be a channel to disseminate knowledge and promotes dialogue among the target audience.

Quotable Quotes

In the 11th Revision of the International Classification of Diseases (ICD-11), the World Health Organisation (WHO) has adopted the definition ‘mild neurocognitive disorders’. This aligns with the DSM-5 diagnostic guidelines by taking into account the pathological character of mild cognitive impairment (MCI).

Learn More

Neurocognitive functions are cognitive functions associated with specific pathways or loci within the brain and are affected by different disease processes.

Learn More

The neurocognitive disorders in DSM-5 comprise three syndromes: delirium, mild neurocognitive disorder (mild NCD) and major neurocognitive disorder (major NCD) or dementia. Once a syndromal diagnosis is made, criteria are presented to delineate etiological diagnoses such as Alzheimer's disease, cerebrovascular disease etc.

Learn More

The clinical symptoms of NCDs fall into two categories: cognitive and neuropsychiatric. Cognitive symptoms include impairments in memory, language, orientation, recognition, and executive functions. The other symptoms of NCDs are called “neuropsychiatric symptoms” (NPSs).

Learn More

Core clinical criteria for all‐cause dementia, based on DSM‐5 criteria for neurocognitive disorders, include cognitive impairments and behavioural symptoms that interfere with functioning and activities of daily living (ADL).

Learn More

Events

Next Events

No live events today.

On-Demand Webcast

Q&A

Q & A

What is the most pragmatic and easy-to-use assessment scale for diagnosing MCI?

Author

May 22 2019 2:47:10

Difficult to say, but probably the Montreal Cognitive Assessment (MoCA) is more sensitive and has higher specificity than the MMSE, which additionally should be used.

Does addressing the cognitive impairment and behavioral & psychological symptoms with EGb 761® helps to delay the progression to dementia?

Author

May 22 2019 2:47:10

There is a clear hint in the literature that if you treat the early symptomatology then you can delay the symptoms of the disease, and so it has somewhat disease modifying properties. So, in this case it slows down the progression to dementia and of course the patient also has lower symptomatology with better quality of life and does not destroy his relationship with relatives and friends.

News Alerts